trazodone has been researched along with Behavior Disorders in 26 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this narrative review is to relate current data on the molecular mechanisms of action of trazodone with its clinical effects and applicability in mental disorders caused or triggered by somatic and neurological disease, according to available publications." | 9.41 | [Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone]. ( Iuzbashian, PG; Romanov, DV; Samsonova, MD, 2023) |
| "The purpose of this narrative review is to relate current data on the molecular mechanisms of action of trazodone with its clinical effects and applicability in mental disorders caused or triggered by somatic and neurological disease, according to available publications." | 5.41 | [Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone]. ( Iuzbashian, PG; Romanov, DV; Samsonova, MD, 2023) |
| " Potential explanations include trazodone administration and transient hypocalcemia." | 3.72 | Unexplained transient hyperphosphatemia is more common in acute psychiatric disorders than in acute medical-surgical conditions. ( Ahmadi, A; Gonzales, J; Lauterbach, EC; Malik, N, 2003) |
| "Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and economic impacts." | 2.82 | Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial. ( Beaulieu-Bonneau, S; Buysse, DJ; Edinger, JD; Ivers, H; Krystal, AD; Morin, CM, 2016) |
| "Trazodone is an antidepressant that is FDA-approved for the treatment of depression." | 2.55 | A review of trazodone use in psychiatric and medical conditions. ( Khouzam, HR, 2017) |
| "Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs)." | 2.48 | Rediscovering trazodone for the treatment of major depressive disorder. ( Catena Dell'Osso, M; Comandini, A; Fagiolini, A; Kasper, S, 2012) |
| "Trazodone is an established antidepressant that is prescribed frequently as an off-label hypnotic with wide acceptance among psychiatrists." | 2.47 | Trazodone: properties and utility in multiple disorders. ( Mittur, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (50.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Romanov, DV | 1 |
| Samsonova, MD | 1 |
| Iuzbashian, PG | 1 |
| Bossini, L | 1 |
| Coluccia, A | 1 |
| Casolaro, I | 1 |
| Benbow, J | 1 |
| Amodeo, G | 1 |
| De Giorgi, R | 1 |
| Fagiolini, A | 2 |
| Morin, CM | 1 |
| Edinger, JD | 1 |
| Krystal, AD | 1 |
| Buysse, DJ | 1 |
| Beaulieu-Bonneau, S | 1 |
| Ivers, H | 1 |
| Khouzam, HR | 1 |
| Mendis, SB | 1 |
| Lukats, V | 1 |
| Roman, MW | 1 |
| Mittur, A | 1 |
| Comandini, A | 1 |
| Catena Dell'Osso, M | 1 |
| Kasper, S | 1 |
| Ahmadi, A | 1 |
| Lauterbach, EC | 1 |
| Malik, N | 1 |
| Gonzales, J | 1 |
| Schwartz, T | 1 |
| Nihalani, N | 1 |
| Virk, S | 1 |
| Jindal, S | 1 |
| Costello, A | 1 |
| Muldoon, R | 1 |
| Azhar, N | 1 |
| Hussein, J | 1 |
| Tirmazi, S | 1 |
| Fernandez, F | 1 |
| Levy, JK | 1 |
| Pasion, RC | 1 |
| Kirby, SG | 1 |
| Verma, SD | 1 |
| Davidoff, DA | 1 |
| Kambhampati, KK | 1 |
| Roccatagliata, G | 1 |
| De Cecco, L | 1 |
| Rossato, P | 1 |
| Albano, C | 1 |
| Pecknold, JC | 1 |
| Ban, TA | 6 |
| Lehmann, HE | 5 |
| Stewart, JA | 5 |
| Vergara, LE | 1 |
| Hontela, S | 4 |
| Nair, NV | 1 |
| Torres, A | 1 |
| Amin, M | 1 |
| Kussin, D | 1 |
| Derkervorkian, K | 1 |
| Schwartz, GV | 1 |
| Sega, S | 1 |
| Chichi, M | 1 |
| Bellico, C | 1 |
| Soprana, M | 1 |
| Fabre, LF | 1 |
| Ravizza, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Therapies for Comorbid and Primary Insomnias[NCT01651442] | 211 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8. (NCT01651442)
Timeframe: 6 weeks, 12 weeks, 3 months, 6 months, 9 months & 12 months
| Intervention | percent remitted (Number) |
|---|---|
| Non-drug Sleep Therapy 1 | 40.00 |
| Sleep Medication 1 | 34.94 |
| Sleep Medication 1 Plus Non-drug Sleep Therapy 1 | 37.04 |
| Sleep Medication 1 Plus Sleep Medication 2 | 48.15 |
| Non-drug Sleep Therapy 1 Plus Non-drug Sleep Therapy 1 | 44.44 |
| Non-drug Sleep Therapy 1 Plus Sleep Medication 1 | 55.56 |
9 reviews available for trazodone and Behavior Disorders
| Article | Year |
|---|---|
[Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Humans; Mental Disorders; Serotonin | 2023 |
Off-Label Trazodone Prescription: Evidence, Benefits and Risks.
Topics: Antidepressive Agents, Second-Generation; Humans; Inappropriate Prescribing; Mental Disorders; Off-L | 2015 |
A review of trazodone use in psychiatric and medical conditions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Child; Child, | 2017 |
New additions to the psychopharmacopia: extended release formulations.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Comparative Effectiveness Re | 2011 |
Trazodone: properties and utility in multiple disorders.
Topics: Animals; Anxiety Disorders; Chronic Pain; Cognition Disorders; Depressive Disorder; Humans; Mental D | 2011 |
Rediscovering trazodone for the treatment of major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; H | 2012 |
Psychopharmacology in HIV spectrum disorders.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Anti-Anxiety Agents; Antipsychotic Agents | 1994 |
Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anti | 1998 |
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
11 trials available for trazodone and Behavior Disorders
| Article | Year |
|---|---|
Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.
Topics: Adult; Affect; Clinical Protocols; Cognitive Behavioral Therapy; Colorado; Combined Modality Therapy | 2016 |
"A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia".
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Drug Monitoring; Female; Humans; Hypnotic | 2004 |
An introduction to systematic studies.
Topics: Aged; Clinical Trials as Topic; Humans; Mental Disorders; Piperazines; Psychiatric Status Rating Sca | 1976 |
An uncontrolled clinical trial carried out in Panama City, Panama.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Ps | 1976 |
An uncontrolled in clinical trial carried out in Verdun, Quebec, Canada.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Piperazines; Psychiatric Sta | 1976 |
A comparison of the two uncontrolled clinical trials.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Ps | 1976 |
A placebo-controlled clinical trial.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Piperazines; Placebos; Psych | 1976 |
A standard-controlled clinical trial.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Piperazines; Psychiatric Sta | 1976 |
A summary of systematic studies.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Ps | 1976 |
Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161).
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Female; Humans; Male; Mental Disorders; Middle Ag | 1975 |
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
7 other studies available for trazodone and Behavior Disorders
| Article | Year |
|---|---|
Diagnostic conundrum: lessons from the man who accidently set fire to his home.
Topics: Accidents; Brain Injuries, Traumatic; Executive Function; Fires; Hepatitis C, Chronic; Housing; Huma | 2016 |
Unexplained transient hyperphosphatemia is more common in acute psychiatric disorders than in acute medical-surgical conditions.
Topics: Acute Disease; Female; Hospitalization; Humans; Hypocalcemia; Male; Mental Disorders; Metabolic Dise | 2003 |
Trazodone for screaming.
Topics: Aged; Aged, 80 and over; Female; Humans; Intellectual Disability; Mental Disorders; Trazodone; Verba | 1993 |
[Trazodone: an Italian drug recently registered in the USSR].
Topics: Depression; Humans; Mental Disorders; Piperazines; Psychophysiologic Disorders; Trazodone | 1979 |
Trazodone intravenously administered and plasma prolactin levels.
Topics: Adult; Aged; Humans; Infusions, Parenteral; Male; Mental Disorders; Middle Aged; Piperazines; Prolac | 1979 |
[Tradozone and geriatric psychopathology].
Topics: Age Factors; Aged; Drug Evaluation; Female; Humans; Male; Mental Disorders; Middle Aged; Piperazines | 1975 |
Diagnostic and therapeutic problems in the psychopharmacological treatment of the elderly patient.
Topics: Aged; Aging; Depressive Disorder; Diagnosis, Differential; Humans; Kinetics; Mental Disorders; Neuro | 1986 |